TScan Therapeutics Appoints Heather Savelle as Vice President, Investor Relations
05 oct. 2021 07h00 HE
|
TScan Therapeutics, Inc.
WALTHAM, Mass., Oct. 05, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies...
TScan Therapeutics to Participate in the Chardan 5th Annual Genetic Medicines Conference
28 sept. 2021 07h00 HE
|
TScan Therapeutics, Inc.
WALTHAM, Mass., Sept. 28, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell...
TScan Therapeutics Appoints Zoran Zdraveski, J.D., Ph.D. as Chief Legal Officer
09 sept. 2021 16h05 HE
|
TScan Therapeutics, Inc.
WALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell...
TScan Therapeutics to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
02 sept. 2021 07h00 HE
|
TScan Therapeutics, Inc.
WALTHAM, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell...
TScan Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress
19 août 2021 07h00 HE
|
TScan Therapeutics, Inc.
Debuted as Publicly Traded Company and Raised $100 Million in Gross Proceeds to Fund Liquid and Solid Tumor Programs IND Submissions Expected in Fourth Quarter 2021 for Lead Liquid Tumor TCR-T...
TScan Therapeutics to Present Discovery of T Cell Targets for COVID-19 at the Cell-Mediated Therapies for Infectious Disease Summit
21 juil. 2021 07h00 HE
|
TScan Therapeutics, Inc.
WALTHAM, Mass., July 21, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies...
TScan Therapeutics, Inc. Announces Pricing of Initial Public Offering
15 juil. 2021 18h59 HE
|
TScan Therapeutics, Inc.
WALTHAM, Mass., July 15, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (TScan), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies...